Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2017

Wood Andrew C, Krytska Kateryna, Ryles Hannah T, Infarinato Nicole R, Sano Renata, Hansel Theodore D, Hart Lori S, King Frederick J, Smith Timothy R, Ainscow Edward, Grandinetti Kathryn B, Tuntland Tove, Kim Sunkyu, Caponigro Giordano, He You Qun, Krupa Shiva, Li Nanxin, Harris Jennifer L, Mossé Yaël P

Abstract excerpt

Purpose: Anaplastic lymphoma kinase (ALK) is the most frequently mutated oncogene in the pediatric cancer neuroblastoma. We performed an in vitro screen for synergistic drug combinations that target neuroblastomas with mutations in ALK to determine whether drug combinations could enhance antitumor efficacy.Experimental Design: We screened combinations of eight molecularly targeted agents against 17...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Cyclin D

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase 4

Share to Cyclin-Dependent Kinase 6

Share to Purines

Share to Retinoblastoma Protein

Share to Small Molecule Libraries

Share to Sulfones

Source

Open in PubMed Open full text

Identifiers

PMID: 27986745
DOI: 10.1158/1078-0432.CCR-16-1114
PMCID: PMC5457336

Genes

ALK
CDK4
CDK6

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma.PMID 27986745Read ↗

Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft modelsSemantic proximity Read ↗

Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.Semantic proximity Read ↗

Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical ModelsSemantic proximity Read ↗

COMBINATION THERAPIES TARGETING ALK-ABERRANT NEUROBLASTOMA IN PRECLINICAL MODELSSemantic proximity Read ↗

Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in NeuroblastomaSemantic proximity Read ↗

A novel combination of CDK4/6 and PI3K inhibitors exhibits highly synergistic activity and translational potential in Ewing sarcomaSemantic proximity Read ↗

Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.Semantic proximity Read ↗

Combination Therapy Targeting the Chk1 and Wee1 Kinases Shows Therapeutic Efficacy in NeuroblastomaSemantic proximity Read ↗

Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.Semantic proximity Read ↗

Synergistic Antitumor Effects of 177Lu-Octreotide Combined with an ALK Inhibitor in a High-Risk Neuroblastoma Xenograft ModelSemantic proximity Read ↗

Preclinical Assessment of Synergistic Efficacy of MELK and CDKs inhibitors in Adrenocortical CancerSemantic proximity Read ↗

Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in NeuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.